Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial

Kidney International

Volumn 66, Issue 2, 2004, Pages 753-760

  Gouva, Chariclia ^b   Nikolopoulos, Petros ^b   Ioannidis, John P A ^b   Siamopoulos, Kostas C ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NONE

Author keywords

Erythropoietin; Renal anemia; Renal failure

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EVALUATION; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEINURIA; TITRIMETRY; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 3242780941     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00797.x     Document Type: Article

References (41)

1. STONE WJ, GRABER SE, KRANTZ SB, et al: Treatment of the anemia of predialysis patients with recombinant human erythropoietin: A randomized, placebo-controlled trial. Am J Med Sci 296:171-179, 1988
2. SILVERBERG DS, BLUM M, AGBARIA Z, et al: The effect of intravenous iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 55:212-219, 2001
3. THE US RECOMBINANT HUMAN ERYTHROPOIETIN STUDY GROUP: Double blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in pre-dialysis patients. Am J Kidney Dis 18:50-59, 1991
4. ROTH D, SMITH RD, SCHULMAN G, et al: Effects of recombinant human erythropoitin on renal function in chronic renal failure pre-dialysis patients Am J Kidney Dis 24:777-784, 1994
5. TEPLAN V, SCHUCK O, KNOTEK A, et al: Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet: Czech multicenter study. Am J Kidney Dis 41(Suppl 3):S26-S30, 2003
6. KLEINMAN KS, SCHWEITZER SU, PERDUE ST, et al: Anemia in predialysis patients and its effect on renal function double-blind, placebo-controlled trial. Am J Kidney Dis 14:486-495, 1989
7. KURIYAMA S, TOMONARI H, YOSHIDA H, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron 77:177-185, 1997
8. BENNETT WM: A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1:990-998, 1991
9. CLYNE N, JOGESTRAND T: Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60:390-396, 1992
10. GARCIA DL, ANDERON S, RENKE HG, BRENNER BM: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 85:6142-6146, 1988
11. NATIONAL KIDNEY FOUNDATION: Kidney Dialysis Outcomes Quality Initiative clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30(Suppl 3):S192-S240, 1997
12. NATIONAL KIDNEY FOUNDATION: NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 37(Suppl 1):S182-S238, 2001
13. WORKING PARTY FOR EUROPEAN BEST PRACTICE GUIDELINES for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 14(Suppl 5):S1-S50, 1999
14. VALDERRABANO F, HORL WH, JACOBS C, et al: European survey on anaemia management (ESAM). Nephrol Dial Transplant 15(Suppl 4):S1-S76, 2000
15. VALDERRABANO F, HORL WH, MACDOUGALL IC, et al: Pre-dialysis survey on anaemia management. Nephrol Dial Transplant 18:89-100, 2003
16. HORL WH, MACDOUGALL IC, ROSSERT J, et al: Predialysis survey on anemia management: Patient referral. Am J Kidney Dis 41:49-61, 2003
17. MATSUMURA M, NOMURA H, KONI I, MABUCHI H: Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Nephron 77:164-168, 1997
18. ALBITAR S, GENIN R, FEN-CHONG M, et al: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 13:1206-1210, 1998
19. MACDOUGALL IC: The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 14:1836-1841, 1999
20. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 24:2413-2446, 1997
21. MARONI BJ: Protein restriction in the pre-end-stage renal disease (ESRD) patient: Who, when, how, and the effect on subsequent ESRD outcome. J Am Soc Nephrol 9(Suppl 12):S100-S106, 1998
22. CASADEVALL N, NATAF J, VIRON B, et al: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
23. ECKARDT KU, CASADEVALL N: Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 18:865-869, 2003
24. PICKETT JL, THEBERGE DC, BROWN WS, et al: Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33:1122-1130, 1999
25. METRY G, WIKSTROM B, VALIND S, et al: Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 10:854-863, 1999
26. MCMAHON LP, MCKENNA MJ, SANGKABUTRA T, et al: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182-1187, 1999
27. MORENO F, SANZ-GUAJARDO D, LOPEZ-GOMEZ JM, et al: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11:335-342, 2000
28. HAYASHI T, SUZUKI A, SHOJI T, et al: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256, 2000
29. PORTOLES J, TORRALBO A, MARTIN P, et al: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548, 1997
30. FINK J, BLAHUT S, REDDY M, LIGHT P: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37:348-355, 2001
31. FINE LG, BANDYOPADHAY D, NORMAN JT: Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 57(Suppl 75):S22-S26, 2000
32. SCHRIER RW, SHAPIRO JI, CHAN L, HARRIS DC: Increased nephron oxygen consumption: Potential role in progression of chronic renal disease. Am J Kidney Dis 23:176-182, 1994
33. KAGEDAL K, JOHANSSON U, OLLINGER K: The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress. FASEB J 15:1592-1594, 2001
34. YANG B, JOHNSON TS, THOMAS GL, et al: Apoptosis and caspase-3 in experimental anti-glomerular basement membrane nephritis. J Am Soc Nephrol 12:485-495, 2001
35. CARLINI RG, ALONZO EJ, DOMINGUEZ J, et al: Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55:546-553, 1999
36. AKIMOTO T, KUSANO E, INABA T, et al: Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 58:269-282, 2000
37. WESTENFELDER C, BIDDLE DL, BARANOWSKI RL: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55:808-820, 1999
38. HEBERT LA, WILMER WA, FALKENHAIN ME, et al: Renoprotection: One or many therapies? Kidney Int 59:1211-1226, 2001
39. BRENNER BM, COOPER ME, ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
40. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
41. ABU-ALFA AK, CRUZ D, PERAZELLA MA, et al: ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. Am J Kidney Dis 35:1076-1082, 2000